# Ginkgo Bioworks Holdings

Type: Company (DNA)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ginkgo-bioworks-holdings
Canonical HTML page: https://getbiobrief.com/entity/ginkgo-bioworks-holdings

## Recent coverage (1 stories)

### Ginkgo Bioworks Surprises Markets with Significant $0.38 EPS Earnings Beat
2026-02-27 03:43:08 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Ginkgo Bioworks (NYSE: DNA) reported a substantial earnings beat for the most recent quarter, outperforming analyst expectations by $0.38 per share. This performance highlights the company's progress in scaling its cell programming platform and optimizing its cost structure amidst a challenging environment for synthetic biology firms.
Full story: https://getbiobrief.com/story/ginkgo-bioworks-dna-earnings-beat-analysis-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.